Coronavirus company news summary – Atossa and Medicago separately publish positive result of their respective Phase I Covid-19 vaccine studies

11 November 2020 (Last Updated November 11th, 2020 09:13)

11 November 2020 

Quebec-based Medicago announced positive interim results from the Phase I clinical trial of its plant-derived Covid-19 vaccine candidate. The results showed that that 100%  of the subjects developed significant antibody and cellular immune responses after being administered two doses of Medicago’s adjuvanted vaccine candidate.

Intas has launched Thymotas, a patented formulation of Thymoquinone that shows efficacy in fighting the SAR-CoV-2 infection. An active biological component of black cumin, Thymotas is clinically tested to be an add-on to the current standard of care for Covid-19. Various research has supported its beneficial properties, but it has been developed as a tablet for the first time by Intas.

The Medigen Vaccine Biologics Corporation and BlueWillow Biologics have collaborated to develop the S-2P-NE-01, a nasal vaccine targeting the SARS-CoV-2 virus. BlueWillow manufactures intranasal vaccines with its patented NanoVax adjuvant. Research shows that intranasal administration stimulates mucosal immunity.

Atossa Therapeutics announced positive results of its proprietary nasal spray candidate, AT-301, in its Phase I clinical study. The drug was found to be both tolerable and safe in this study when administered in single and multiple dose forms over a period of 14 days. AT-301 is being developed for recently diagnosed Covid-19 patients for at home use.